Eli Lilly and Company LLY
Composite 60/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 23/100 — a strong mark against it.
Growth ranks 94/100 — a strong point in its favour. Quality ranks 84/100 — a strong point in its favour. Momentum ranks 70/100 — a moderate point in its favour.
Valuation ranks 23/100 — a strong mark against it. Balance-sheet strength ranks 39/100 — a slight mark against it. Income ranks 43/100 — a slight mark against it.
What the company does Eli Lilly discovers, develops, manufactures, and markets human pharmaceuticals globally, with core franchises in diabetes, obesity, oncology, and immunology. Key products include Mounjaro and Zepbound for type 2 diabetes and obesity, Verzenio for breast cancer, and Taltz for immunology.
Key financials Revenue growth 44.7% and EPS growth 96.2% highlight strong execution. Margins are robust: gross 83.4%, operating 54.2%, net 33.5%. ROE is 102.3% and ROA 20.4%, reflecting efficient capital use. Debt/Equity is 1.62 with net debt/EBITDA at 1.10, and current ratio is 1.35.
Stock health Momentum is mixed: 12-month return 59.03%, but down 10.51% from the 52-week high and RSI(14) at 42.80. Sideravia scores show high quality (85.3) and growth (92.2), but valuation is weak (18.9) and income low (38.6).
Price vs fair value The stock trades at a **discount of 13.70%** to the analyst mean target of 1315.04. - Recent $2.9B immunology deal adds pipeline depth (2026-09-01). - FDA approvals strengthen GLP-1 positioning (2026-09-01). - Insurer pullback on GLP-1 drugs may pressure near-term sales (2026-09-01). - High margins and ROE support premium valuation (Key financials).
Looking forward Forward P/E of 32.36 and PEG of 1.47 suggest growth is priced at a premium. Pipeline catalysts in obesity and immunology could drive further upside if execution remains strong.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.